Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect, HydraSpace, and select toxSYN linker-payloads
Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized therapeutic index
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin ), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, and Synaffix B.V. (CEO: Peter van de Sande, Synaffix ), a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug conjugates (ADCs), today announced the signing of a license and option agreement.
(0)
The Supervisory Board of Synthon BV, an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic and hybrid medicines for patients around the world, is pleased to announce that Anish Mehta is appointed as Chief Executive Officer and member of the Board of Directors, effective immediately. We are delighted to welcome Anish to Synthon , said Hans Stols, Executive Chairman. Anish s successful track record, deep industry expertise and his energetic and result-driven personality will help Synthon to continue delivering on our purpose of developing therapies that improve health and well-being globally.
Anish is a global healthcare veteran with more than 20 years of experience in innovative and generic pharmaceuticals. Prior to joining Synthon, Anish was the Chief Executive Officer of Theramex, a global specialty pharma company dedicated to Women s Health, where he established the company following the acquisition an